Stradling Helps Rebound Therapeutics Raise $16.5 Million in Series B Financing

Stradling advised Rebound Therapeutics Corp. in the first close of its $16.5 million Series Preferred Stock financing. HBM-MedFocus, Invus Opportunities Fund and affiliates of Wexford Capital LP led the round.

Rebound Therapeutics is an Orange County medical device company with a proprietary technology platform comprised of state-of-the-art imaging and illumination technologies for use during many minimally invasive surgical (MIS) procedures. When used together, Rebound’s single-use, disposable MIS access and therapeutic devices are expected to disrupt the way many MIS procedures are currently performed, including the displacement of the large, complex, capital equipment being used in operating rooms today. The Rebound platform technologies can be adapted for a variety of surgical procedures including neurosurgery, spine and orthopedic surgery, thoracic and general abdominal surgery.

The Newport Beach-based team representing Rebound included Jeff Estes and Arash Lessantiz, with Larry Cohn contributing valuable wisdom.